C4 Therapeutics (CCCC) Cash from Investing Activities Growth (3y) (2022 - 2026)
Powered by 
Analysis
C4 Therapeutics (CCCC) Cash from Investing Activities Growth (3y) (2022 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | 46.78% |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | 66.14% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | -44.69% |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | -39.73% |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | -246.81% |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | -53.57% |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 27.84% |
| 10 | C4 Therapeutics | 489.46 Mn | 235.80 Mn | - | -43.87% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -43.87% |
| Mar 31, 2026 | -32.93% |
| Dec 31, 2025 | -120.33% |
| Sep 30, 2025 | -41.02% |
| Jun 30, 2025 | 5.41% |
| Mar 31, 2025 | 110.10% |
| Dec 31, 2024 | 30.65% |
| Sep 30, 2024 | 26.03% |
| Jun 30, 2024 | -33.16% |
| Mar 31, 2024 | 4.72% |
| Dec 31, 2023 | 37.33% |
| Sep 30, 2023 | 55.86% |
| Jun 30, 2023 | 28.98% |
| Mar 31, 2023 | 564.13% |
| Dec 31, 2022 | 265.65% |